340B Contract Pharmacies and Rebate Models: Which Rule Applied to the Transaction?

A 340B contract pharmacy rebate model delivers the discounted drug price through a payment after dispensing, under a manufacturer plan that requires federal approval. For someone who works with pharmacy claims, purchasing or rebate payments, that changes where the missing money can sit. The invoice, the dispense and the rebate decision each tell part of the story. A higher invoice can reach the billing team before the rebate lowers the actual cost.

How the Ordinary 340B Transaction Works

The 340B program lets eligible hospitals, health centers and other covered entities buy covered outpatient drugs at discounted prices. The ceiling price is the preceding quarter’s average manufacturer price minus the Medicaid unit rebate amount. Manufacturer-reported price inputs therefore affect both what Medicaid receives in rebates and what safety-net health care providers pay for drugs. Ceiling prices are available to authorized participants through the Health Resources and Services Administration’s information system, rather than a public price list.

The discount attaches to the covered entity’s purchase. A contract pharmacy supplies the dispensing service. The agency’s original contract-pharmacy guidance in 1996 described a ship-to, bill-to arrangement: the manufacturer bills the covered entity and ships the drugs to the pharmacy. Title passes to the covered entity. This gave providers without suitable in-house pharmacy services a way to get medicines to their patients.

The ordinary replenishment model adds another layer. As the agency describes the workflow, the pharmacy dispenses from neutral inventory. Software then identifies eligible prescriptions, often with a third-party administrator doing the eligibility work. Once enough eligible dispenses accumulate, the covered entity orders replacement stock at the discounted price through its wholesaler account. The replacement drugs go back to the pharmacy.

The person at the counter, the administrator qualifying the dispense and the purchaser ordering replenishment see different parts of that transaction. A review has to reconnect them. Looking only at the bottle that left the shelf misses the later purchase through which the covered entity captured the discount.

Covered entities can generate revenue when insurers reimburse more than the discounted acquisition cost. The 340B statute leaves the use of that revenue open, while grant requirements can impose their own conditions. The program’s express restrictions address duplicate discounts and diversion: the same drug unit cannot attract both the 340B discount and a Medicaid rebate, and discounted drugs must go to the covered entity’s patients. The statute itself does not define who counts as a patient.

The Rebate Model Changes the Purchase and the Payment

The rebate model replaces discounted replenishment purchases with purchases at wholesale acquisition cost, followed by a manufacturer rebate. Under the revised pilot, that rebate equals WAC minus the ceiling price on the day of dispense. It is paid at the unit level, without requiring a full package to accumulate for the rebate payment.

The pharmacy can still dispense first. The agency’s explanation of the revised pilot expressly allows a dispense from neutral inventory, followed by WAC replenishment and then a rebate request. Purchases continue through the existing 340B wholesale account, with the relevant WAC prices loaded into it. Rebate requests are limited to WAC purchases in that account. Purchases through a WAC-only or group purchasing organization account, or at a GPO or other discounted price, do not qualify for pilot rebates.

The financial question is when the wholesaler must be paid compared with when the rebate arrives. Covered entities told the agency that the change could create cash-flow pressure. The agency expects prompt payment and unit-level rebates to reduce that pressure, potentially putting the rebate in the entity’s hands before its wholesaler invoice comes due. The actual invoice terms, submission history and payment dates show what happened to a particular purchase.

Medicare’s negotiated maximum fair price adds a separate comparison. The negotiated price and the 340B concession do not stack on the same eligible drug unit. Where the negotiated price is lower, the manufacturer provides access to it without duplicating the 340B concession. A Medicaid duplicate-discount issue and a Medicare negotiated-price adjustment require different payer records, even when both appear in the same rebate system.

Who Must Approve a 340B Rebate Model?

The Secretary of Health and Human Services must approve a 340B rebate mechanism before a manufacturer implements it. The Health Resources and Services Administration has allowed a rebate option for state AIDS drug assistance programs since 1998. The dispute over newer manufacturer proposals concerned who could authorize the change.

In its July 21, 2026 decision on the manufacturer rebate proposals, the D.C. Circuit held that manufacturers could not impose those models first and wait for the Secretary to disapprove them. Approval had to come before implementation. The distinction matters to a purchasing employee who received a manufacturer’s notice announcing a new payment mechanism: the announcement and the federal approval are separate documents.

The first pilot also has to be kept separate from its replacement. The agency announced that earlier pilot in August 2025, with an intended January 2026 start. A federal court in Maine paused it nationwide in December 2025. The Department of Health and Human Services withdrew it, and the court set aside its notices and manufacturer approvals in February 2026.

The revised Federal Register notice followed on August 3, 2026. It provides a new framework for approved plans. An approval under the withdrawn pilot does not supply the approval for a transaction under its replacement.

What the Revised Pilot Requires

The revised pilot covers the listed NDC-11s of active drugs selected for Medicare negotiation for initial price applicability years 2026 and 2027, during their applicable price periods. Its scope follows the selected drug regardless of payer or indication. It reaches covered outpatient drugs administered in a physician’s office or clinic as well as prescriptions dispensed at a pharmacy. The Health Resources and Services Administration reported $100 billion in discounted purchases across the wider program in 2025. The pilot covers a selected group of drugs within it.

As of October 18, 2026, the agency lists approved manufacturer plans with a January 1, 2027 start date. Examples include AstraZeneca’s Farxiga and Amgen’s Enbrel and Otezla. The listed manufacturers all use the Beacon Rebate Model Platform. The approved plan identifies the drugs and any covered-entity exceptions. Drugs without an approved pilot plan remain subject to upfront discounted pricing. For a transaction review, the drug’s presence on the Medicare list, the manufacturer approval and the plan’s effective date each matter.

Different Events Start Different Clocks

Manufacturers must give covered entities and other affected parties 90 calendar days’ notice before implementing an approved plan. The claims-submission window must allow at least 45 calendar days from dispense, with allowances for extenuating circumstances and changes in a claim’s 340B status.

The payment clock starts with completed data submission. Manufacturers must pay the rebate or deny it with supporting documentation within ten calendar days. If a submission is returned as incomplete, that clock restarts when the necessary data arrives. The agency includes data validation within the payment period. An incomplete-data return therefore matters to the timing of the money, and its reason belongs beside the original submission.

For the transition, plans must accommodate up to two unreplenished accumulated packages through a 15-calendar-day grace period before the pilot takes effect. That provision addresses dispenses from neutral stock that still need their discount accounted for when the purchasing mechanism changes.

The Data Request Has Boundaries

The permitted claim fields identify the dispense and its payment path, including the drug, quantity, provider, covered entity and payer. Purchasing data and encounter data are outside the pilot’s permitted submission fields. Cash and uninsured claims use CASH in fields accepting letters and numbers, while numeric fields use the value designated in the manufacturer’s plan.

Manufacturers must bear the cost of the submission platform. The platform must provide real-time rebate-status reports and a quarterly ceiling-price file for each relevant drug identifier. Covered entities can use that file to account for the post-rebate acquisition cost in Medicaid billing and patient cost sharing. A higher purchase invoice and a lower final acquisition cost have to be reconciled somewhere in the business.

Plans must allow incomplete submissions to be corrected and explain how wasted or undispensed units are reported. The notice also limits use of submitted data to the pilot’s stated purposes, including limits on sharing or licensing it.

The Reason for a Denial Matters

The pilot bars rebate denials based on covered-entity eligibility, diversion or Medicaid duplicate-discount concerns. Manufacturers must raise those concerns with the Health Resources and Services Administration or through the program’s audit and dispute mechanisms. Other denials need specific supporting documentation, such as a Medicare negotiated-price concession or a rebate already provided to another covered entity on the same claim.

A manufacturer may check that the dispensing site appears in the agency’s 340B OPAIS system. But the notice draws a clear line around purchase-data concerns:

Covered entities still need auditable purchase records, and the agency says rebate requests follow purchases in the proper wholesale account. The manufacturer must take concerns about insufficient purchases to the agency or through the program’s review mechanisms. The denial code, the explanation behind it and the purchase ledger answer different parts of the dispute.

The agency requires manufacturer reporting on payments and denials and can revoke participation for noncompliance. For an insider, the useful evidence is the pattern in actual submissions and decisions, including who set the rules the platform applied.

Which Court Order Governs a 340B Contract Pharmacy Restriction?

For a 340B contract pharmacy restriction, the operative court order depends on the pharmacy’s state and the restriction at issue. Federal courts have not required delivery to unlimited contract pharmacies, while state access laws in Arkansas and Louisiana have survived manufacturers’ challenges. State law can impose a delivery duty beyond the federal obligation.

The Health Resources and Services Administration’s guidance expanded from a single contract-pharmacy site in 1996 to multiple pharmacy arrangements in 2010, with controls against diversion and duplicate discounts. Manufacturers began imposing restrictions in 2020. The program’s statute does not expressly mention contract pharmacies, which became central to the court disputes.

The restrictions were concrete operating policies. In the Third Circuit’s 2023 account, Sanofi permitted unlimited contract pharmacies when the covered entity supplied claims data, but otherwise allowed an in-house pharmacy or one contract pharmacy when there was no in-house option. AstraZeneca’s policy allowed an in-house pharmacy or a single contract pharmacy when the entity had none. The pharmacy agreement establishes the covered entity’s dispensing relationship. The manufacturer’s policy explains the delivery condition being disputed.

The Department of Health and Human Services issued an advisory opinion in December 2020 asserting that manufacturers had to deliver discounted drugs to contract pharmacies acting for covered entities. It withdrew that opinion in June 2021.

In January 2023, the Third Circuit held that federal law did not require delivery to unlimited contract pharmacies. In May 2024, the D.C. Circuit upheld the distribution conditions before it while leaving open whether more onerous conditions, or their application in particular circumstances, could violate the statute.

State access laws produced a different set of decisions. The Eighth Circuit upheld Arkansas’s law in 2024. The Fifth Circuit’s July 2026 Louisiana opinion likewise upheld that state’s law against the manufacturers’ federal-law challenges. Those holdings explain why a manufacturer policy and a federal opinion are only part of the transaction’s setting: the pharmacy’s state can impose its own delivery obligation.

The Eighth Circuit’s July 2026 Missouri decision refused to block the law while the case proceeded. The Fourth Circuit’s March 2026 West Virginia opinion was set aside in May 2026, so it cannot supply the governing answer.

We connect the actual manufacturer restriction, pharmacy location and transaction date to the relevant law and order. A policy restricting delivery to a pharmacy and a plan converting an approved drug’s purchase to a rebate mechanism affect different parts of the transaction. Each needs its own authority and effective date.

What the Claims and Purchase Records Can Show

The strongest transaction evidence connects the drug, the covered entity’s patient, the dispensing pharmacy, the payer, the purchase and the later rebate decision. Eligibility records explain why a dispense entered the program. The wholesaler account and invoice show the purchase. The submission, rejection reason, correction and payment history show how the manufacturer handled the requested discount.

The payer record is especially important for duplicate discounts. In its January 2020 report, the Government Accountability Office found that the Health Resources and Services Administration assessed potential duplicate discounts in Medicaid fee-for-service but did not fully assess managed-care claims. Managed care accounted for 71% of Medicaid prescriptions in fiscal year 2018. The audit gap covered the majority of prescriptions. The Government Accountability Office also found that audits generally closed on the covered entity’s own word that it had corrected the problems.

The revised-pilot notice describes another consequence of poor claim identification. The Medicaid Exclusion File was built for fee-for-service claims and inadequately captures managed-care transactions. Identification failures can leave duplicate discounts undetected or exclude eligible claims from state rebate invoices. In the latter case, taxpayers lose rebate money that should help pay for Medicaid care.

The billing side supplies a concrete parallel. In February 2024, the Justice Department announced that Pomona Valley Hospital Medical Center had agreed to pay nearly $2.1 million to resolve allegations that it billed higher usual-and-customary charges instead of the lower acquisition costs required for the drugs. The hospital disclosed the problem after an internal audit.

That case puts the acquisition price beside the Medicaid bill. Under the revised pilot, a reviewer must also connect the later rebate to the cost used for billing. The person responsible for pharmacy purchasing may see the WAC invoice, while the billing team needs the price after the rebate. We examine that connection with you, including the instructions and decisions behind a mismatch.

When False Billing Costs the Government

In a healthcare False Claims Act case, we examine how knowing false billing or reporting affected a government payment or money owed to the government. The acquisition price, Medicaid claim and rebate obligation supply the financial connection. The business’s instructions and its response to a known discrepancy help explain who understood what was happening.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

When You Know Why the Numbers Differ

If you work with contract-pharmacy claims, manufacturer rebates or Medicaid billing and know why a discount went missing or the wrong cost reached a claim, speak with our whistleblower experts about the transactions. We trace the gap between the invoice, the rebate and the Medicaid bill to build your strongest 340B whistleblower case. We bring in pharmaceutical fraud whistleblower lawyers who understand drug pricing and government payment, and stay beside you throughout the case.